retatrutide compound Peptide The FDA has issued warning

doi: 10.1210/endo-128-1-394

The process of eating, which releases nutrients, stimulates glucagon-like peptide-1, an appetite hormone we naturally have in our bodies, which decreases appetite and creates fullness

So, pharmaceutical companies started investigating the use of GLP-1s for weight-management purposes, and the first GLP-1 weight-loss drug, Saxenda (liraglutide), was approved by FDA in 2014 (it was previously approved to treat diabetes under the name Victoza)

In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called ileal braking effect (35)

it's a prioritization framework that accounts for the reduced food volume GLP-1 therapy produces

PMID: 124 ShiaoY